US4418068A
(en)
|
1981-04-03 |
1983-11-29 |
Eli Lilly And Company |
Antiestrogenic and antiandrugenic benzothiophenes
|
TW366342B
(en)
|
1992-07-28 |
1999-08-11 |
Lilly Co Eli |
The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
|
US5478847A
(en)
|
1994-03-02 |
1995-12-26 |
Eli Lilly And Company |
Methods of use for inhibiting bone loss and lowering serum cholesterol
|
US5998402A
(en)
|
1996-04-19 |
1999-12-07 |
American Home Products Corporation |
2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
|
TW397821B
(en)
|
1996-04-19 |
2000-07-11 |
American Home Produits Corp |
3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
|
US5880137A
(en)
|
1996-04-19 |
1999-03-09 |
American Home Products Corporation |
2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
|
US5780497A
(en)
|
1996-04-19 |
1998-07-14 |
American Home Products Corporation |
2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
|
JP2001509805A
(ja)
|
1997-02-05 |
2001-07-24 |
ワーナー−ランバート・コンパニー |
細胞増殖阻害剤としてのピリド〔2,3−d〕ピリミジンおよび4−アミノピリミジン
|
GB9718913D0
(en)
|
1997-09-05 |
1997-11-12 |
Glaxo Group Ltd |
Substituted oxindole derivatives
|
US6005102A
(en)
|
1997-10-15 |
1999-12-21 |
American Home Products Corporation |
Aryloxy-alkyl-dialkylamines
|
US6326392B1
(en)
|
1997-11-06 |
2001-12-04 |
American Home Products Corporation |
Anti-estrogen plus progestin containing oral contraceptives
|
ID24568A
(id)
|
1997-11-06 |
2000-07-27 |
American Home Prod |
Kontrasepsi oral yang mengandung anti-estrogen plus progestin
|
US6583170B1
(en)
|
1998-05-15 |
2003-06-24 |
Wyeth |
2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
|
US6479535B1
(en)
|
1998-05-15 |
2002-11-12 |
Wyeth |
2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
|
CZ20022332A3
(cs)
*
|
2000-01-07 |
2003-01-15 |
Transform Pharmaceuticals, Inc. |
Sestava vzorků
|
CO5271697A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
|
CO5271709A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
|
CO5271696A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Procedimiento para reducir la morbilidad y el riesgo de mortalidad
|
CO5251465A1
(es)
|
2000-01-26 |
2003-02-28 |
Pfizer Prod Inc |
Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
|
US20020013327A1
(en)
|
2000-04-18 |
2002-01-31 |
Lee Andrew G. |
Compositions and methods for treating female sexual dysfunction
|
ATE423120T1
(de)
|
2000-06-26 |
2009-03-15 |
Pfizer Prod Inc |
Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe
|
AU2001271781A1
(en)
|
2000-07-06 |
2002-01-21 |
Wyeth |
Use of substituted indole compounds for treating sphincter incontinence
|
US6509332B2
(en)
|
2000-07-06 |
2003-01-21 |
Wyeth |
Methods of treating excessive intraocular pressure
|
WO2002003976A2
(en)
|
2000-07-06 |
2002-01-17 |
Wyeth |
Combinations of bisphosphonates, estrogenic agents and optionally estrogens
|
US20020016318A1
(en)
|
2000-07-06 |
2002-02-07 |
American Home Products Corporation |
Methods of treating breast disorders
|
JP2004502729A
(ja)
|
2000-07-06 |
2004-01-29 |
ワイス |
Ssriおよびエストロゲン剤の組み合わせ
|
MXPA02012890A
(es)
|
2000-07-06 |
2003-10-24 |
Wyeth Corp |
Uso de compuestos de indol sustituidos para incrementar la actividad de oxido nitrico sintasa.
|
EP1359940A2
(en)
|
2000-07-06 |
2003-11-12 |
Wyeth |
Combinations of statins, estrogenic agents and optionally estrogens
|
AR030064A1
(es)
|
2000-07-06 |
2003-08-13 |
Wyeth Corp |
Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
|
WO2002003988A2
(en)
|
2000-07-06 |
2002-01-17 |
Wyeth |
Use of substituted indole compounds for treating neuropeptide y-related conditions
|
AU2001271784A1
(en)
|
2000-07-06 |
2002-01-21 |
Wyeth |
Therapy for prosthesis-related bone degeneration
|
EP1177787A3
(en)
|
2000-07-28 |
2003-09-10 |
Pfizer Products Inc. |
Use of an estrogen agonist/antagonist for treating cataracts
|
ATE278421T1
(de)
|
2000-08-11 |
2004-10-15 |
Wyeth Corp |
Verfahren zur behandlung eines östrogenrezeptor positives karzinoms
|
EP1192945A3
(en)
|
2000-09-21 |
2004-03-03 |
Pfizer Products Inc. |
Use of an estrogen agonist/antagonist for treating osteoarthritis
|
IL145838A
(en)
|
2000-10-16 |
2008-11-03 |
Pfizer Prod Inc |
Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis
|
AU781168B2
(en)
|
2001-01-26 |
2005-05-12 |
Pfizer Products Inc. |
Method of treating certain cancers using an estrogen agonist/antagonist
|
ATE314370T1
(de)
|
2002-01-22 |
2006-01-15 |
Warner Lambert Co |
2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one
|
JP2006516561A
(ja)
|
2003-01-17 |
2006-07-06 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
細胞増殖の阻害剤としての2−アミノピリジン置換ヘテロ環類
|
JP4053073B2
(ja)
|
2003-07-11 |
2008-02-27 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
選択的cdk4阻害剤のイセチオン酸塩
|
WO2005040166A1
(en)
|
2003-10-23 |
2005-05-06 |
F.Hoffmann-La Roche Ag |
Triaza-spiropiperidine derivatives for use as glyt-1 inhibitors in the treatment of neurological and neuropsychiatric disorders
|
GB0327380D0
(en)
|
2003-11-25 |
2003-12-31 |
Cyclacel Ltd |
Method
|
ITMI20040874A1
(it)
|
2004-04-30 |
2004-07-30 |
Ist Naz Stud Cura Dei Tumori |
Derivati indolici ed azaindolici con azione antitumorale
|
CA2579221A1
(en)
|
2004-09-08 |
2006-03-16 |
Merck & Co., Inc. |
Monocyclic anilide spirolactam cgrp receptor antagonists
|
US7696192B2
(en)
|
2004-09-09 |
2010-04-13 |
Merck Sharp & Dohme Corp. |
Tricyclic anilide spirolactam CGRP receptor antagonists
|
CN101018781A
(zh)
|
2004-09-13 |
2007-08-15 |
默克公司 |
双环n-酰苯胺螺内酰胺cgrp受体拮抗剂
|
US7390798B2
(en)
|
2004-09-13 |
2008-06-24 |
Merck & Co., Inc. |
Carboxamide spirolactam CGRP receptor antagonists
|
AU2006205851A1
(en)
|
2005-01-14 |
2006-07-20 |
Janssen Pharmaceutica N.V. |
5-membered annelated heterocyclic pyrimidines as kinase inhibitors
|
EP1846397A1
(en)
|
2005-01-21 |
2007-10-24 |
Janssen Pharmaceutica N.V. |
Novel heterocyclic benzoy[c]chromene derivatives useful as modulators of the estrogen receptors
|
EP1779848A1
(en)
|
2005-10-28 |
2007-05-02 |
Nikem Research S.R.L. |
V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
|
EP1954135B1
(en)
|
2005-11-18 |
2012-10-10 |
Merck Sharp & Dohme Corp. |
Spirolactam aryl cgrp receptor antagonists
|
US8198466B2
(en)
|
2006-02-03 |
2012-06-12 |
Bionomics Limited |
Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
|
CA2673108A1
(en)
|
2006-12-08 |
2008-06-19 |
Merck & Co., Inc. |
Constrained spirocyclic compounds as cgrp receptor antagonists
|
WO2008109464A1
(en)
|
2007-03-02 |
2008-09-12 |
University Of Massachusetts |
Spirolactam targeting compounds and related compounds
|
BRPI0813647A2
(pt)
|
2007-06-25 |
2014-12-23 |
Neurogen Corp |
Piperazinil oxoalquil tetrahidro-beta-carbolinas e análogos relacionados
|
WO2009061345A2
(en)
|
2007-11-07 |
2009-05-14 |
Cornell Research Foundation, Inc. |
Targeting cdk4 and cdk6 in cancer therapy
|
WO2009085185A1
(en)
|
2007-12-19 |
2009-07-09 |
Amgen Inc. |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
US8518930B2
(en)
|
2008-07-29 |
2013-08-27 |
Nerviano Medical Sciences S.R.L. |
Therapeutic combination comprising a CDKS inhibitor and an antineoplastic agent
|
PL2331547T3
(pl)
|
2008-08-22 |
2015-01-30 |
Novartis Ag |
Związki pirolopirymidynowe jako inhibitory CDK
|
AU2009298367A1
(en)
|
2008-10-01 |
2010-04-08 |
The University Of North Carolina At Chapel Hill |
Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
|
AU2009310352A1
(en)
|
2008-10-01 |
2010-05-06 |
The University Of North Carolina At Chapel Hill |
Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
|
CN102458443A
(zh)
|
2009-05-13 |
2012-05-16 |
北卡罗来纳大学查珀尔希尔分校 |
细胞周期蛋白依赖性激酶抑制剂及使用方法
|
SG179172A1
(en)
|
2009-09-16 |
2012-04-27 |
Avila Therapeutics Inc |
Protein kinase conjugates and inhibitors
|
WO2011103485A1
(en)
|
2010-02-18 |
2011-08-25 |
Medivation Technologies, Inc. |
Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
CN102939287B
(zh)
|
2010-06-10 |
2016-01-27 |
塞拉根制药公司 |
***受体调节剂及其用途
|
US8853423B2
(en)
|
2010-06-17 |
2014-10-07 |
Seragon Pharmaceuticals, Inc. |
Indane estrogen receptor modulators and uses thereof
|
GB2483736B
(en)
|
2010-09-16 |
2012-08-29 |
Aragon Pharmaceuticals Inc |
Estrogen receptor modulators and uses thereof
|
US10005750B2
(en)
|
2010-10-06 |
2018-06-26 |
J-Pharma Co., Ltd. |
Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
|
JP5923509B2
(ja)
|
2010-10-25 |
2016-05-24 |
ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. |
Cdk阻害剤
|
US8691830B2
(en)
*
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
US8829102B2
(en)
|
2010-10-27 |
2014-09-09 |
Cabot Corporation |
High loading carbon black masterbatch for pressure pipe applications
|
US9540361B2
(en)
|
2010-12-24 |
2017-01-10 |
Merck Sharp & Dohme B.V. |
N-substituted azetidine derivatives
|
US9102683B2
(en)
|
2011-08-29 |
2015-08-11 |
University Of Utah Research Foundation |
Heterocyclic compounds
|
US9193714B2
(en)
|
2011-12-14 |
2015-11-24 |
Seragon Pharmaceuticals, Inc. |
Fluorinated estrogen receptor modulators and uses thereof
|
MD20140054A2
(ru)
|
2011-12-16 |
2014-10-31 |
Olema Pharmaceuticals, Inc. |
Новые соединения бензопирана, композиции и их применение
|
EP3216792B1
(en)
|
2012-03-29 |
2020-05-27 |
G1 Therapeutics, Inc. |
Lactam kinase inhibitors
|
US10202392B2
(en)
|
2012-04-26 |
2019-02-12 |
Francis Xavier Tavares |
Synthesis of lactams
|
WO2013169574A2
(en)
|
2012-05-09 |
2013-11-14 |
Merck Sharp & Dohme Corp. |
Aliphatic spirolactam cgrp receptor antagonists
|
DK2872482T3
(da)
*
|
2012-07-13 |
2020-09-21 |
Oncternal Therapeutics Inc |
En fremgangsmåde til behandling af brystkræft med selektiv androgenreceptormodulator (sarm)
|
WO2014019176A1
(zh)
|
2012-08-01 |
2014-02-06 |
华为技术有限公司 |
用于同步的方法、装置及***
|
ES2691742T5
(es)
|
2012-11-01 |
2022-03-18 |
Infinity Pharmaceuticals Inc |
Tratamiento de cánceres utilizando moduladores de isoformas de PI3 cinasa
|
US9527857B2
(en)
*
|
2013-03-15 |
2016-12-27 |
GI Therapeutics, Inc. |
HSPC-sparing treatments for RB-positive abnormal cellular proliferation
|
WO2014144596A2
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Transient protection of hematopoietic stem and progenitor cells against ionizing radiation
|
WO2014144740A2
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Highly active anti-neoplastic and anti-proliferative agents
|
LT3004090T
(lt)
|
2013-05-28 |
2018-01-10 |
Astrazeneca Ab |
Cheminiai junginiai
|
WO2014205138A1
(en)
|
2013-06-19 |
2014-12-24 |
Seragon Pharmaceuticals, Inc. |
Estrogen receptor modulator and uses thereof
|
BR112015030595A2
(pt)
|
2013-06-19 |
2017-07-25 |
Seragon Pharmaceuticals Inc |
moduladores de receptor de estrogênio de azetidina e usos dos mesmos
|
WO2014203129A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Combinations of benzopyran compounds, compositions and uses thereof
|
WO2014203132A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Substituted benzopyran compounds, compositions and uses thereof
|
WO2015061407A1
(en)
|
2013-10-24 |
2015-04-30 |
Francis Xavier Tavares |
Process for synthesis of lactams
|
WO2015136016A2
(en)
|
2014-03-13 |
2015-09-17 |
F. Hoffmann-La Roche Ag |
Therapeutic combinations with estrogen receptor modulators
|
US20150297606A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
|
WO2016040848A1
(en)
*
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
KR20230113416A
(ko)
|
2014-12-18 |
2023-07-28 |
에프. 호프만-라 로슈 아게 |
테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체조절제 및 이의 용도
|
WO2017021177A1
(en)
*
|
2015-08-04 |
2017-02-09 |
Universitat De Barcelona |
Pharmaceutical combinations for use in the treatment of cancer
|
MX2018007079A
(es)
|
2015-12-09 |
2018-11-12 |
The Board Of Trustees Of Univ Of Illinois |
Reguladores a la baja del receptor de estrogeno selectivo de benzotiofeno.
|
CN110325191A
(zh)
*
|
2017-02-22 |
2019-10-11 |
G1治疗公司 |
以较少的副作用治疗egfr-驱动的癌症
|